U.S. Retail REITs Stock News

NYSE:MANU
NYSE:MANUEntertainment

Is A £51m Manu Kone Deal Reshaping The Investment Case For Manchester United (MANU)?

In recent weeks, reports indicate Manchester United have reached an agreement in principle on personal terms with Roma midfielder Manu Kone, as the club intensifies its search for a third midfield signing following departures and injuries. This potential £51m acquisition highlights Manchester United’s commitment to reshaping its midfield core amid strong competition from European and Saudi clubs, reinforcing the club’s effort to build a deeper squad for upcoming campaigns. We’ll now...
NasdaqGS:PLUS
NasdaqGS:PLUSElectronic

Did ePlus’ (PLUS) Expanded Share Authorization Quietly Redefine Its Capital Flexibility Playbook?

At its 2026 Annual Meeting of Shareholders held on September 10, 2026, ePlus Inc. secured board approval for a proposal to amend its Certificate of Incorporation to lift authorized common shares from 50,000,000 to 75,000,000, keeping preferred shares unchanged at 2,000,000 and raising total authorized capital stock to 77,000,000, subject to shareholder approval. This planned increase in authorized common stock gives ePlus added flexibility to fund future business and financial initiatives,...
NasdaqGS:NSIT
NasdaqGS:NSITElectronic

Insight Enterprises (NSIT) Following AI And Cloud Demand Narrative Faces A Valuation Test

Insight Enterprises (NSIT) has drawn fresh attention after a recent move in its share price, with the stock last closing at $117.65. Investors are weighing this level against the company’s fundamentals and recent return profile. See our latest analysis for Insight Enterprises. The recent 1-day share price return of 1.72% and 90-day share price return of 60.66% place Insight Enterprises firmly in a momentum phase, although the 1-year total shareholder return declined 19.32%, showing a...
NasdaqGS:IONS
NasdaqGS:IONSBiotechs

Ionis Pharmaceuticals (IONS) Trial Setback Sparks Scrutiny, Is The 38% Undervaluation Case Still Credible?

Ionis Pharmaceuticals (IONS) is under renewed scrutiny after reporting that its late stage CARDIO TTRansform trial for eplontersen with AstraZeneca did not meet the primary efficacy endpoint, triggering a sharp share price reaction and a shareholder investigation. See our latest analysis for Ionis Pharmaceuticals. The eplontersen trial failure and shareholder investigation come after a sharp shift in momentum for Ionis Pharmaceuticals, with the share price down 26.10% over 30 days and 29.02%...
NYSE:BBWI
NYSE:BBWISpecialty Retail

Bath & Body Works (BBWI) Enters Brazil, Is The Stock Undervalued?

Bath & Body Works (BBWI) stock is drawing renewed attention after the company announced its entry into Brazil, opening its first store and digital channel in a market known for strong fragrance and self-care demand. See our latest analysis for Bath & Body Works. At a share price of $19.90, Bath & Body Works has seen its 30-day share price return fall 8.76%, and its 1-year total shareholder return decline 34.43%. This suggests recent momentum has been weak even as investors react to the Brazil...
NYSE:CTRE
NYSE:CTREHealth Care REITs

CareTrust REIT (CTRE) Stock Looks Reasonably Priced With Some Value Left

CareTrust REIT has delivered a strong share price run over the past three years, yet the current checks paint a mixed valuation picture that leaves investors weighing a solid return record against only a partial signal that the stock is still cheap on fundamentals. The stock has returned 137.7% over three years, which puts recent gains at the center of any discussion about whether new buyers are paying up for that performance. Future rent growth and cash flows from its healthcare-focused...
NasdaqCM:FRHC
NasdaqCM:FRHCCapital Markets

Freedom Holding (FRHC) After The Antom Deal With A Pricey 62.7x P E

Freedom Holding (FRHC) drew fresh investor attention after signing Memoranda of Understanding with Antom, a payment services provider under Ant International, to build cross border payment solutions for Kazakhstani users shopping on Chinese e commerce platforms. See our latest analysis for Freedom Holding. At a share price of $151.02, Freedom Holding has pulled back slightly over the last week but still shows a 30 day share price return of 11.49% and a year to date share price return of...
NasdaqGS:SSNC
NasdaqGS:SSNCProfessional Services

SS&C Technologies (SSNC) Stock Faces Valuation Debate As EPS Growth Supports Bullish Narratives

SS&C Technologies Holdings (SSNC) has reported a clean set of Q2 2026 numbers, with revenue of US$1.7 billion and basic EPS of US$0.99, alongside trailing 12 month EPS of US$3.58. Over the past few quarters the company has seen revenue move from US$1.54 billion in Q2 2025 to US$1.70 billion in Q2 2026, while basic EPS has risen from US$0.74 to US$0.99. This puts the focus on how a 13.2% trailing net margin shapes the quality of these results for investors. See our full analysis for SS&C...
NasdaqGS:ALHC
NasdaqGS:ALHCHealthcare

Alignment Healthcare (ALHC) Stock Looks Below Fair Value After Legal Questions

Alignment Healthcare stock has delivered a very strong 237.9% return over the past three years, yet its valuation checks still suggest the shares screen as cheap rather than stretched. That contrast is now running head on into fresh legal and regulatory questions that could affect how investors think about the quality and sustainability of the company’s earnings. A 237.9% three year gain positions Alignment Healthcare as a major winner over that period, so any hint that its growth story is...
NasdaqGS:AVT
NasdaqGS:AVTElectronic

Avnet (AVT) Stock Still May Be A Bargain On Earnings

Avnet stock has delivered a strong 145.2% return over the past 5 years, yet the company scores poorly on broader valuation checks, leaving investors weighing a solid track record against signals that the shares may not be a simple bargain at the current US$89.42 price. Over 5 years, Avnet has returned 145.2%, which puts recent gains into context as investors assess how much of the story is already reflected in the share price. Avnet's ability to convert its electronics distribution business...
NYSE:IVT
NYSE:IVTRetail REITs

InvenTrust Properties (IVT) Looks Fairly Valued Following Dividend Growth Focus

Recent coverage of InvenTrust Properties (IVT) is centering on its pattern of annual dividend increases, a moderate payout ratio, and analyst expectations for earnings growth, all of which are drawing fresh attention from income-focused investors. See our latest analysis for InvenTrust Properties. At a share price of $36.45, InvenTrust Properties has posted a 12.12% 90 day share price return and a 30.74% year to date share price return. The 1 year total shareholder return of 36.62% and 3 year...
NYSE:THC
NYSE:THCHealthcare

Tenet Healthcare (THC) Stock Faces Cautious Narratives Despite Strong Q2 EPS And Margin Performance

Tenet Healthcare (THC) has reported another strong quarter, with Q2 2026 revenue of US$6.1 billion, basic EPS of US$9.89 and net income excluding extraordinary items of US$826 million setting the tone. The company’s quarterly revenue increased from US$5.3 billion in Q2 2025 to US$6.1 billion in Q2 2026, while basic EPS rose from US$3.16 to US$9.89 over the same period. Trailing 12 month earnings growth of 51% has coincided with a net profit margin that improved to 9.9% from 7.2% a year...
NYSE:ORI
NYSE:ORIInsurance

Old Republic International (ORI) Posted Mixed Results, Is The Recent Bounce Already Priced In?

Old Republic International (ORI) just reported mixed quarterly results, with stronger Title Insurance profitability offset by weaker Specialty Insurance performance. Technology and data investments, the ECM acquisition, and ongoing buybacks shaped how investors reacted. See our latest analysis for Old Republic International. Old Republic International’s mixed quarter and active buyback have come alongside a 1 day share price return of 2.35% and a 30 day share price return of 4.94%. The 1 year...
NasdaqGS:ARM
NasdaqGS:ARMSemiconductor

Investing In Automation With 3 Robotics Stocks Showing Real Growth

Robotics and automation stocks sit at the crossroads of several forces investors are watching closely, from labor shortages and inflation pressures to shifting supply chains and energy uncertainty. As physical AI moves from pilot projects to wider deployment, some companies in the Robotics and Automation Stocks screener are aiming to turn that demand into revenue while keeping balance sheets under control. This article introduces the robotics theme in the context of central bank moves,...
NasdaqGS:ARCB
NasdaqGS:ARCBTransportation

ArcBest Stock And 2 Logistics Picks For Tariff Driven Supply Chain Shifts

Global trade tensions are heating up again, with fresh US tariffs of 10% to 12.5% on imports from more than 60 countries and a swift response from China adding to supply chain uncertainty. For logistics and freight providers, this mix of higher costs, rerouted trade flows, and shifting customer demand can create both pressure and opportunity. This article discusses 3 stocks from our Global Logistics and Freight Providers screener that are directly exposed to the latest tariff moves and...
NYSE:RGA
NYSE:RGAInsurance

Is Slowing Capital Generation And Book Value Pressure Altering The Investment Case For Reinsurance Group of America (RGA)?

Recently, analysts highlighted that Reinsurance Group of America is facing growth constraints versus smaller peers, with earnings per share lagging revenue gains and book value per share projected to fall over the next year amid softer capital generation. This commentary raises questions about the strength of RGA’s internal capital engine at a time when it remains a major life and health reinsurer globally. We’ll now examine how concerns over weakening capital generation and book value...
NYSE:XXI
NYSE:XXICapital Markets

Twenty One Capital (XXI) After The CEO Change And What Its Valuation May Be Saying

Twenty One Capital (XXI) is back in focus after CEO Jack Mallers resigned on July 20, 2026, and board member Raphael Zagury stepped in as chief executive on the same date. See our latest analysis for Twenty One Capital. The CEO transition at Twenty One Capital comes after a sharp reset in investor expectations, with the share price down 42.05% over the past 90 days and the year to date share price return declining 51.40%. The 1 year total shareholder return has fallen 83.97%, pointing to...
NasdaqGM:AXSM
NasdaqGM:AXSMPharmaceuticals

Axsome Therapeutics (AXSM) Wins FDA NDA Acceptance, Is The Stock Fully Valued?

Why Axsome Therapeutics Stock Is Back in Focus After the Latest FDA Milestone Axsome Therapeutics (AXSM) is drawing fresh attention after the U.S. Food and Drug Administration accepted its New Drug Application for AXS-12, an investigational treatment for cataplexy in narcolepsy, and set a PDUFA target action date of May 1, 2027. See our latest analysis for Axsome Therapeutics. For investors, the FDA’s acceptance of AXS-12 comes as Axsome Therapeutics’ share price has risen 29.6% over the past...
NasdaqGS:COLM
NasdaqGS:COLMLuxury

Columbia Sportswear (COLM) Stock Looks Like A Cash Flow Bargain Yet Fair On Earnings

Columbia Sportswear stock has been weak over the past few years, yet the latest Discounted Cash Flow (DCF) intrinsic value estimate points to meaningful upside compared with where the shares currently trade. At the same time, broader valuation checks suggest a mixed picture rather than a clear bargain or clear overvaluation. Over the past 5 years, Columbia Sportswear shares have declined about 32%, which puts recent returns out of step with the current DCF indication of undervaluation. For...
NasdaqGS:TMUS
NasdaqGS:TMUSWireless Telecom

T-Mobile US (TMUS) Stock Faces Margin Pressure As 11.5% Net Margin Tests Bullish Narratives

T-Mobile US (TMUS) has just posted Q2 2026 results with revenue of US$22.8 billion and basic EPS of US$2.99, alongside net income of US$3.2 billion that keeps profitability firmly in focus for investors. Over the past six quarters, the company has seen revenue range between US$20.1 billion and US$24.3 billion while quarterly EPS moved between US$1.89 and US$3.00, providing context for how this latest result fits into its recent history. With a trailing twelve month net margin of 11.5% and...